CA
NZ
UK
AU
IND
US
…
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -144.81M | -69.98M | -65.30M | -0.87M | 3.35M |
| Net income | -143.28M | -73.42M | -64.39M | -1.74M | 3.26M |
| Selling general administrative | 34.07M | 47.61M | 38.01M | 27.51M | 36.30M |
| Selling and marketing expenses | 23.51M | 23.64M | 7.51M | 14.62M | 11.74M |
| Gross profit | 36.86M | 160.16M | 56.02M | 76.23M | 69.60M |
| Reconciled depreciation | 21.04M | 14.28M | 9.80M | 8.61M | 6.83M |
| Ebit | -113.44M | -61.39M | -55.11M | 1.50M | 7.57M |
| Ebitda | -113.17M | -46.87M | -45.32M | 10.11M | 14.40M |
| Depreciation and amortization | 0.27M | 14.53M | 9.79M | 8.61M | 6.83M |
| Operating income | -113.44M | -61.39M | -55.11M | 1.50M | 6.26M |
| Other operating expenses | 474.75M | 409.48M | 165.43M | 126.92M | 106.77M |
| Interest expense | 19.05M | 16.96M | 10.74M | 2.63M | 3.79M |
| Tax provision | -1.54M | 3.45M | -0.91M | 0.87M | 0.09M |
| Interest income | 0.26M | 0.25M | 0.12M | 0.20M | 0.18M |
| Net interest income | -18.79M | -16.71M | -10.62M | -2.43M | -3.61M |
| Income tax expense | 1.54M | 3.45M | 0.91M | 0.87M | 0.09M |
| Total revenue | 361.30M | 348.08M | 110.32M | 126.20M | 113.03M |
| Total operating expenses | 150.31M | 221.56M | 111.13M | 76.95M | 63.34M |
| Cost of revenue | 324.44M | 187.92M | 54.30M | 49.97M | 43.43M |
| Total other income expense net | -31.37M | -8.59M | -10.19M | -2.37M | 0.69M |
| Net income from continuing ops | -143.28M | -73.42M | -64.39M | -1.74M | 3.26M |
| Net income applicable to common shares | - | -73.42M | -64.39M | -1.74M | 3.26M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 469.39M | 621.34M | 817.35M | 449.16M | 264.72M |
| Intangible assets | 25.57M | 28.71M | 32.70M | 35.41M | 41.81M |
| Other current assets | 50.63M | 74.08M | 71.04M | 57.83M | 14.92M |
| Total liab | 341.14M | 401.55M | 646.77M | 371.74M | 129.57M |
| Total stockholder equity | 128.25M | 219.80M | 170.58M | 77.42M | 135.15M |
| Deferred long term liab | - | 1.39M | 1.58M | 1.74M | 1.95M |
| Other current liab | 88.64M | 189.50M | 218.69M | 51.71M | 26.98M |
| Common stock | 20.84M | 20.75M | 15.79M | 13.65M | 13.64M |
| Capital stock | 20.84M | 20.75M | 15.79M | 13.65M | 13.64M |
| Retained earnings | -551.68M | -450.25M | -306.97M | -233.55M | -176.22M |
| Other liab | - | - | 173.38M | 100.11M | 7.36M |
| Other assets | - | -0.00M | -0.00M | 26.78M | 24.10M |
| Cash | 126.08M | 289.43M | 346.64M | 204.39M | 64.44M |
| Total current liabilities | 158.86M | 277.39M | 368.98M | 175.87M | 41.30M |
| Current deferred revenue | 5.70M | 9.41M | 124.02M | 89.58M | 1.14M |
| Net debt | 82.74M | -137.05M | -231.99M | -98.94M | 20.78M |
| Short term debt | 46.96M | 36.99M | 10.24M | 9.68M | 4.31M |
| Short long term debt | 44.08M | 11.58M | 7.11M | 6.99M | 2.00M |
| Short long term debt total | 208.82M | 152.38M | 114.66M | 105.45M | 85.22M |
| Other stockholder equity | 593.36M | 594.04M | 409.26M | 244.98M | 297.73M |
| Property plant equipment | - | - | 173.83M | 78.15M | 69.34M |
| Total current assets | 262.82M | 424.66M | 585.83M | 308.43M | 129.16M |
| Long term investments | - | 0.00M | 2.12M | 2.13M | 2.26M |
| Net tangible assets | - | 192.48M | 139.46M | 43.75M | 95.29M |
| Net receivables | 41.65M | 23.91M | 44.01M | 19.23M | 24.03M |
| Long term debt | 132.77M | 87.23M | 50.73M | 46.38M | 24.32M |
| Inventory | 44.47M | 35.10M | 124.10M | 26.93M | 25.77M |
| Accounts payable | 17.56M | 41.49M | 16.04M | 24.90M | 8.87M |
| Accumulated other comprehensive income | 65.73M | 55.25M | 52.51M | 52.34M | -31.16M |
| Common stock total equity | - | - | - | 13.65M | 13.64M |
| Non currrent assets other | 8.49M | 8.30M | 19.28M | 19.47M | 17.16M |
| Non current assets total | 206.57M | 196.69M | 231.52M | 140.74M | 135.56M |
| Capital lease obligations | 31.97M | 53.57M | 56.82M | 52.09M | 58.90M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -29.05M | -93.12M | -19.34M | -10.69M | -2.92M |
| Change to liabilities | -133.90M | 74.35M | 94.67M | 10.24M | 2.41M |
| Total cashflows from investing activities | - | -93.12M | -19.34M | -10.69M | -2.92M |
| Net borrowings | - | -3.90M | 26.16M | -2.61M | -14.15M |
| Total cash from financing activities | 215.12M | 154.50M | 21.74M | -7.70M | 30.95M |
| Change to operating activities | -108.71M | 134.85M | 99.76M | 6.37M | -0.00M |
| Net income | -143.28M | -73.42M | -64.39M | -1.74M | 3.26M |
| Change in cash | -57.21M | 142.29M | 140.00M | -12.64M | 43.54M |
| Begin period cash flow | 346.64M | 204.39M | 64.44M | 77.08M | 33.55M |
| End period cash flow | 289.43M | 346.69M | 204.44M | 64.44M | 77.08M |
| Total cash from operating activities | -245.34M | 76.90M | 137.74M | 5.53M | 16.31M |
| Issuance of capital stock | 189.84M | 166.82M | 0.29M | 0.02M | 49.29M |
| Depreciation | 21.04M | 14.28M | 9.80M | 8.61M | 6.83M |
| Other cashflows from investing activities | - | 0.06M | 0.11M | 0.20M | 0.18M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | 84.22M | -92.37M | -4.20M | -2.42M | -2.79M |
| Change to account receivables | 12.40M | -21.35M | -24.02M | -17.28M | 4.34M |
| Sale purchase of stock | - | - | - | -2.48M | -0.02M |
| Other cashflows from financing activities | 30.12M | -7.56M | 45.56M | 6.45M | -2.75M |
| Change to netincome | 22.88M | 40.56M | 26.12M | 1.83M | 2.26M |
| Capital expenditures | 29.32M | 93.17M | 19.47M | 10.88M | 3.17M |
| Change in working capital | -145.98M | 36.13M | 166.21M | -3.00M | 2.99M |
| Stock based compensation | -8.66M | 14.51M | 6.33M | 2.55M | 1.89M |
| Other non cash items | 33.07M | 81.96M | 20.70M | -1.76M | 1.25M |
| Free cash flow | -274.67M | -16.27M | 118.27M | -5.36M | 13.13M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VALN Valneva SE ADR |
-0.05 0.84% |
5.87 | - | 10000.00 | 3.85 | 4.30 | 4.48 | -11.92 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas Lingelbach | Chairman of the Management Board, Pres & CEO | 1963 |
| Mr. Franck Grimaud MBA | Director Gen., Chief Bus. Officer & Member of Management Board | 1967 |
| Mr. Frederic Jacotot | VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board | 1965 |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer & Member of the Management Board | 1971 |
| Mr. Peter Buhler | CFO & Management Board Member | 1971 |
| Mr. Perry Celentano | Interim Chief Operating Officer | NA |
| Ms. Dipal Patel | Chief Commercial Officer & Member of Management Board | NA |
| Mr. Joshua Drumm Ph.D. | VP of Investor Relations | NA |
| Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations | NA |
| Mr. Gerald Strohmaier | VP of Human Resource | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...